Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. The company has in-licensed three products: SILENOR for the treatment of insomnia, Nalmefene HCI for the treatment of pathological gambling and a new formulation of acamprosate Ca for the treatment of certain movement disorders. The company s strategy is to focus on advancing the clinical development of its existing product candidates and build a pharmaceutical portfolio by sourcing products that are currently commercialized outside the United States, approved in the United States with significant commercial potential for proprietary new uses or alternative delivery systems. Somaxon Pharmaceuticals maintains its corporate headquarters in San Diego.